Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors
暂无分享,去创建一个
Kuntal Pal | Karsten Melcher | H. Xu | K. Melcher | K. Pal | H Eric Xu | H. E. Xu | XU HEric
[1] I. Gozes,et al. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability , 2008, Journal of peptide science : an official publication of the European Peptide Society.
[2] B. Wulff,et al. Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity , 2003, British journal of pharmacology.
[3] P. Sexton,et al. Pattern of Intra-Family Hetero-Oligomerization Involving the G-Protein-Coupled Secretin Receptor , 2008, Journal of Molecular Neuroscience.
[4] S. Goldring,et al. Full Activation of Chimeric Receptors by Hybrids between Parathyroid Hormone and Calcitonin , 1996, The Journal of Biological Chemistry.
[5] B. Gallwitz. The evolving place of incretin-based therapies in type 2 diabetes , 2010, Pediatric Nephrology.
[6] R. Riek,et al. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[7] P. Hajduk,et al. Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS , 2007, Proceedings of the National Academy of Sciences.
[8] Anthony J Harmar,et al. Family-B G-protein-coupled receptors , 2001, Genome Biology.
[9] R. Lefkowitz,et al. Distinct β-Arrestin- and G Protein-dependent Pathways for Parathyroid Hormone Receptor-stimulated ERK1/2 Activation* , 2006, Journal of Biological Chemistry.
[10] L. Nabors,et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. , 1998, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians.
[11] T. Usdin,et al. Molecular determinants of tuberoinfundibular peptide of 39 residues (TIP39) selectivity for the parathyroid hormone-2 (PTH2) receptor. N-terminal truncation of TIP39 reverses PTH2 receptor/PTH1 receptor binding selectivity. , 2000, The Journal of biological chemistry.
[12] F. Grégoire,et al. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency , 2004, Peptides.
[13] Leonardo Pardo,et al. Ligand-regulated oligomerization of β2-adrenoceptors in a model lipid bilayer , 2009, The EMBO journal.
[14] H. Xu,et al. Crystal Structure of the PAC1R Extracellular Domain Unifies a Consensus Fold for Hormone Recognition by Class B G-Protein Coupled Receptors , 2011, PloS one.
[15] C. Koth,et al. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. , 2010, Structure.
[16] R. Riek,et al. NMR Structure of the First Extracellular Domain of Corticotropin-releasing Factor Receptor 1 (ECD1-CRF-R1) Complexed with a High Affinity Agonist* , 2010, The Journal of Biological Chemistry.
[17] S. Yokoyama,et al. Crystal structure of the human receptor activity‐modifying protein 1 extracellular domain , 2008, Protein science : a publication of the Protein Society.
[18] H. Xu,et al. Molecular recognition of parathyroid hormone by its G protein-coupled receptor , 2008, Proceedings of the National Academy of Sciences.
[19] H. Schiöth,et al. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.
[20] Lotte Bjerre Knudsen,et al. Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor* , 2009, The Journal of Biological Chemistry.
[21] L. Jingjing,et al. Study on preparation and activity of a novel recombinant human parathyroid hormone(1–34) analog with N-terminal Pro–Pro extension , 2007, Regulatory Peptides.
[22] T. Gardella,et al. Parathyroid Hormone (PTH)-(1–14) and -(1–11) Analogs Conformationally Constrained by α-Aminoisobutyric Acid Mediate Full Agonist Responses via the Juxtamembrane Region of the PTH-1 Receptor* , 2001, The Journal of Biological Chemistry.
[23] N. Tinel,et al. Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization , 2008, Nature Methods.
[24] Vsevolod V Gurevich,et al. How and why do GPCRs dimerize? , 2008, Trends in pharmacological sciences.
[25] C. Goudet,et al. Allosteric functioning of dimeric class C G‐protein‐coupled receptors , 2005, The FEBS journal.
[26] I. Campbell,et al. Three-dimensional structure of a complement control protein module in solution. , 1991, Journal of molecular biology.
[27] R. Rudolph,et al. Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor , 2007, Proceedings of the National Academy of Sciences.
[28] B. Wiesner,et al. Dimerization of Corticotropin-Releasing Factor Receptor Type 1 Is Not Coupled to Ligand Binding , 2005, Journal of receptor and signal transduction research.
[29] H. Xu,et al. Structural Basis for Hormone Recognition by the Human CRFR2α G Protein-coupled Receptor* , 2010, The Journal of Biological Chemistry.
[30] R. Rudolph,et al. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? , 2009, Trends in biochemical sciences.
[31] H. Xu,et al. Structural Basis for Parathyroid Hormone-related Protein Binding to the Parathyroid Hormone Receptor and Design of Conformation-selective Peptides* , 2009, The Journal of Biological Chemistry.
[32] Richard R. Neubig,et al. International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List , 2005, Pharmacological Reviews.
[33] L. Miller,et al. Critical Contributions of Amino-terminal Extracellular Domains in Agonist Binding and Activation of Secretin and Vasoactive Intestinal Polypeptide Receptors. STUDIES OF CHIMERIC RECEPTORS (*) , 1995, The Journal of Biological Chemistry.
[34] L. B. Knudsen,et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. , 2000, Journal of medicinal chemistry.
[35] M. Wheeler,et al. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. , 2001, Biochemistry.
[36] P. Sexton,et al. Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs. , 2006, Annals of the New York Academy of Sciences.
[37] H. Randeva,et al. Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins. , 2000, Molecular endocrinology.
[38] Robert J. Lefkowitz,et al. Transduction of Receptor Signals by ß-Arrestins , 2005, Science.
[39] Patrick M. Sexton,et al. International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors , 2002, Pharmacological Reviews.
[40] Monitoring the structural consequences of Phe12-->D-Phe and Leu15-->Aib substitution in human/rat corticotropin releasing hormone. Implications for design of CRH antagonists. , 2001, European journal of biochemistry.
[41] Helgi B. Schiöth,et al. Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.
[42] A. Couvineau,et al. VPAC receptors for VIP and PACAP. , 2002, Receptors & channels.
[43] H. Vaudry,et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. , 2000, Pharmacological reviews.
[44] W. Creutzfeldt,et al. Gastric inhibitory polypeptide. , 1980, Clinics in gastroenterology.
[45] H. Xu,et al. Molecular Recognition of Corticotropin-releasing Factor by Its G-protein-coupled Receptor CRFR1* , 2008, Journal of Biological Chemistry.
[46] Krzysztof Palczewski,et al. Structure of the rhodopsin dimer: a working model for G-protein-coupled receptors. , 2006, Current opinion in structural biology.
[47] S. Bonner-Weir,et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.
[48] B. Wulff,et al. Three Distinct Epitopes on the Extracellular Face of the Glucagon Receptor Determine Specificity for the Glucagon Amino Terminus* , 2003, Journal of Biological Chemistry.
[49] M. Palkovits,et al. The TIP39–PTH2 receptor system: Unique peptidergic cell groups in the brainstem and their interactions with central regulatory mechanisms , 2010, Progress in Neurobiology.
[50] M. Nauck,et al. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. , 2004, Diabetes.
[51] Roland Baron,et al. The Alternatively Spliced Δe13 Transcript of the Rabbit Calcitonin Receptor Dimerizes with the C1a Isoform and Inhibits Its Surface Expression* , 2003, Journal of Biological Chemistry.
[52] N. Ling,et al. NMR Structural Characterization of a Minimal Peptide Antagonist Bound to the Extracellular Domain of the Corticotropin-releasing Factor1 Receptor* , 2007, Journal of Biological Chemistry.
[53] Darrell R. Abernethy,et al. International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.
[54] Y. Yamada. [Gastric inhibitory polypeptide (GIP) receptor]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.
[55] E. Krause,et al. A Role for a Helical Connector between Two Receptor Binding Sites of a Long-chain Peptide Hormone* , 2000, The Journal of Biological Chemistry.
[56] L. Miller,et al. Transmembrane Segment IV Contributes a Functionally Important Interface for Oligomerization of the Class II G Protein-coupled Secretin Receptor* , 2007, Journal of Biological Chemistry.
[57] Laurence J Miller,et al. Constitutive Formation of Oligomeric Complexes between Family B G Protein-Coupled Vasoactive Intestinal Polypeptide and Secretin Receptors , 2006, Molecular Pharmacology.
[58] W. Vale,et al. CRF and CRF receptors: role in stress responsivity and other behaviors. , 2004, Annual review of pharmacology and toxicology.
[59] Masatsugu Horiuchi,et al. London Radiation Symposium , 1963, Cell and tissue kinetics.
[60] Kjeld Madsen,et al. Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain* , 2008, Journal of Biological Chemistry.
[61] G. Hall. 12 – X-Ray Analysis , 1984 .
[62] L. Frohman,et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. , 2006, The Journal of clinical endocrinology and metabolism.
[63] Gregory I. Mashanov,et al. Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules , 2010, Proceedings of the National Academy of Sciences.
[64] R. Lefkowitz,et al. A β-Arrestin–Biased Agonist of the Parathyroid Hormone Receptor (PTH1R) Promotes Bone Formation Independent of G Protein Activation , 2009, Science Translational Medicine.
[65] L. Miller,et al. Dimeric Arrangement of the Parathyroid Hormone Receptor and a Structural Mechanism for Ligand-induced Dissociation* , 2010, The Journal of Biological Chemistry.
[66] S. Hoare,et al. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. , 2005, Drug discovery today.
[67] C. Hewage,et al. Conformational and molecular interaction studies of glucagon‐like peptide‐2 with its N‐terminal extracellular receptor domain , 2011, FEBS letters.
[68] T. Usdin,et al. TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus , 1999, Nature Neuroscience.
[69] N. Irwin,et al. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. , 2008, Biochemical pharmacology.
[70] Alon Chen,et al. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. , 2004, Endocrinology.
[71] R. Riek,et al. Common and divergent structural features of a series of corticotropin releasing factor-related peptides. , 2007, Journal of the American Chemical Society.
[72] A. Couvineau,et al. Class-B GPCR activation: is ligand helix-capping the key? , 2008, Trends in biochemical sciences.
[73] R. Riek,et al. Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand , 2007, Proceedings of the National Academy of Sciences.
[74] J. Reeve,et al. Parathyroid hormone - a bone anabolic and catabolic agent. , 2005, Current opinion in pharmacology.
[75] T. Serwold,et al. Chimeric human calcitonin and glucagon receptors reveal two dissociable calcitonin interaction sites. , 1995, Biochemistry.
[76] Ian J. Tickle,et al. X-ray analysis of glucagon and its relationship to receptor binding , 1975, Nature.
[77] B. Persson,et al. Model of the complex of Parathyroid hormone-2 receptor and Tuberoinfundibular peptide of 39 residues , 2010, BMC Research Notes.
[78] T. Ikegami,et al. Conformation of a peptide ligand bound to its G-protein coupled receptor , 2001, Nature Structural Biology.
[79] C. Donaldson,et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[80] W. Vale,et al. Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation , 2008, Proceedings of the National Academy of Sciences.